Here are five details:
1. For the quarter, the company generated $35.8 million in revenue, a 13 percent increase year over year. U.S. revenue reached $31.7 million, a 12 percent jump year-over-year.
2. SeaSpine’s spinal implants segment generated $17.3 million in revenue for the quarter, a 12 percent increase year-over-year.
3. Within the orthobiologics segment, SeaSpine reported $18.5 million, a 13 percent increase year-over-year.
4. The company’s orthobiologics growth was attributed to recently launched products, including the OsteoStrand Plus, along with higher sales in demineralized bone matrix products.
5. SeaSpine expects its full-year revenue to range between $141 million and $142 million, representing a 7 percent to 8 percent increase year-over-year.
To read the full report, click here.
More articles on devices and implants:
DePuy Synthes to outsource production, closes manufacturing plant: 5 things to know
Wishbone Medical makes acquisition
Joimax moves into bigger US headquarters: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
